PACIFIC BIOSCIENCES OF CALIFORNIA Q2 FY26 earnings call PACB

Mark Van Owen assumed the role of President and CEO, succeeding Christian Henry, effective immediately. The transition is described as seamless, with Van Owen focusing on scaling growth, sharpening execution, and operating a leaner, more focused organization built around highest conviction growth drivers. His priorities include leveraging successful EMEA strategies globally, driving Spark Next adoption, and expanding understanding of disease biology through enhanced HiFi throughput, cost efficiency, and data access. The company initiated a targeted reorganization to integrate marketing more closely with commercial, aiming to maximize growth opportunities in the clinical market.

The full global commercial rollout of Spark Next chemistry was a key highlight of the quarter, with strong customer enthusiasm. By June, over a third of the install base opted into the new software that facilitates Spark Next usage. Spark Next provides a significant increase in sequencing throughput per run, enabling multi-use smart cells and reducing the US list price to $345 per 20x HiFi human genome, a 30% reduction. This improved economic profile is expected to drive volume in the second half of 2026 and beyond, with the first wave of reorders anticipated in the coming months^⏳ as customers complete validation and work through existing inventory.

PACBio sold 20 Revio systems in Q2 FY26, an increase from 15 in the prior year, with 60% going to new customers and 45% as part of multi-instrument purchase orders. Cumulative Revio shipments reached 366 systems. The company also sold 26 Vega systems, down from 38 in the prior year, with 81% going to new customers. Multi-system Revio orders, including a significant placement to a new population-scale customer, signal the company's entry into larger genomic studies. Clinical customers are also transitioning from R&D to more routine production sequencing with HiFi technology.

Two recent publications reinforced the clinical utility of HiFi long-read sequencing. An article in the New England Journal of Medicine demonstrated 96.4% concordance with standard of care for rare disease diagnostics, improving or refining diagnoses in 3.4% of cases. Another article in Nature Genetics supported the move to a 'one-test paradigm' for medical genetics. These validations strengthen the company's conviction that long-read sequencing can shift the standard of care. Clinical consumables shipments grew 67% year-over-year, representing a mid-teens percentage of total consumables, indicating strong adoption in this market.

The company faced several financial headwinds, including ongoing NIH and academic funding constraints in the Americas, which led to a slight revenue decline in the region. Asia Pacific revenue decreased 45% year-over-year due to the conclusion of a significant program and funding issues. Non-GAAP gross margin was impacted by previously discussed compute cost inflation and $1.1 million in costs associated with transitioning Vega manufacturing in-house. To mitigate these, a restructuring was initiated to reduce the workforce by approximately 40 employees, aiming to lower ongoing operating expenses by $15 million-$20 million in FY27, while preserving investment in high-priority growth initiatives.

The Spark Next chemistry is scheduled to launch on the Vega system later in August. This update will enable higher throughput of up to 90 gigabases per run and lower DNA input requirements, enhancing the system's capabilities. Management expects this to expand the application set for Vega and drive increased utilization, particularly in public health laboratories for applications like wastewater testing. Despite funding uncertainty impacting new Vega orders, customer conversations remain constructive, and the average selling price for Vega has returned to normalized levels.